Transcript Highlights:

• schools, are specialized public schools affiliated with universities and designed to serve as laboratories
• With us we have the FAMU Developmental Research School, Florida Atlantic University Laboratory School
• , FSU Laboratory Schools, and P.K.
• The directors of Florida laboratory schools are happy to have this opportunity today to share with you
• Joel Earps from the Florida Atlantic University Laboratory School.

Summary: The Senate Committee on Education Postsecondary met to receive an update from Florida developmental research lab schools on articulated health care programs created under the Live Healthy initiative and Senate Bill 76. Chair Calatayud opened the meeting, confirmed a quorum, and heard presentations from P.K. Young/University of Florida, Florida State University Schools, FAMU Developmental Research School, and Florida Atlantic University Laboratory School. Each school described efforts to build K-12-to-postsecondary health care pathways, expand dual enrollment and industry certifications, and share replicable curriculum models with other districts. FSU Schools highlighted its HERO program, including CNA and food manager certifications, dual enrollment growth, reserve seating at colleges, and a paid internship with the Department of Health tied to emergency shelter operations. P.K. Young described its Healthy Lives Blueprint, which combines K-8 wellness experiences, a new high school health and human performance pathway, AP and science course expansion, a planned gymnasium redesign, and partnerships with Santa Fe College and UF. FAMU DRS reported growing dual enrollment, partnerships with FAMU, Tallahassee State, and Lively, and a goal of serving at least 100 students and 40 staff through health career exposure, certifications, and AA/AS pathways. FAU Lab School described a more advanced model that integrates elementary through high school research and health science experiences, including biotechnology, bioengineering, and partnerships with health and research institutions. The school reported 87 peer-reviewed student publications, more than $350,000 in student grants, six patents, and pipelines into FAU’s medical and nursing programs, including a Med Direct pathway and a National Merit Scholar pipeline. Committee members asked about student readiness for nursing programs, dual enrollment, articulation with state colleges, and how the lab school models could be disseminated statewide. The meeting concluded with praise for the programs and a motion by Senator Fine to adjourn, which was adopted without objection.

Transcript Highlights:

• I'm Kayla Wilburn, the Clinic Director for the Center for Health and Prevention Clinics at Community
• Center for Health and Prevention Clinics at Community Action Partnership in San Luis Obispo.
• Distribution on our mobile clinic in some of the most rural areas of San Luis Obispo County.
• . clinics that are not adequate to meet the need.
• The two direct CDC grants support infectious disease mitigation and laboratory services.

Keywords: 988, house, all

Transcript Highlights:

• cells under 21 CFR 1271 federal guidelines, focusing on safety, donor screening, and, in some cases, clinical
• Senate Bill 878 deals with clinical laboratory personnel.
• licensure requirements to serve as lab techs, technologists, and medical laboratory scientists.
• Senate Bill 878 deals with clinical laboratory personnel, Senators.
• licensure requirements to serve as lab techs, technologists, and medical laboratory scientists.

Keywords: 999, senate, all

Transcript Highlights:

• </c><00:55:01.760><c> COVID</c> epidemiology and laboratory COVID epidemiology and laboratory COVID expansion
• Its aims were to enhance<00:55:13.040><c> laboratory</c><00:55:13.760><c> surveillance</c> enhance laboratory
• It is this clinical rotations.
• </c> prohibition on hospital-based clinics prohibition on hospital-based clinics and<01:28:23.679><c>
• </c><01:52:50.880><c> have</c> other hospital-based clinics that have other hospital-based clinics that

Keywords: 1187, senate, all

Transcript Highlights:

• First, it allows a private laboratory to conduct a blood or breath analysis if the lab is accredited
• governments are not required to use a private laboratory.
• Is there any limitation on whether the laboratory, these other laboratories, need to be in Washington
• Some are clinical in nature and have accreditation consistent with those.
• When testing is performed by an out-of-state laboratory or private clinic that refuses to participate

Keywords: 904, all

Transcript Highlights:

• Issue number 4 is laboratory testing.
• Recommendations continue rider 2, laboratory testing, which requires the Animal Health Commission to
• Rider 9, cattle fever tick mitigation clinical trials.
• The main primary clinical sign was a decrease in milk production.
• This ectoparasite field identification laboratory will enhance our mitigation and deterrence efforts

Summary: The committee met with a quorum present to hear Article VI Natural Resources agency budget recommendations, beginning with the Railroad Commission. LBB staff summarized the commission’s 2026-27 base recommendation at $458.7 million, down from the prior biennium, with an increased FTE cap. The presentation highlighted reduced federal IIJA funding, volatility in oil and gas regulation account 5155, continued support for IT modernization, and rider changes. The commission’s major exceptional items were then presented, including requests for produced water and injection data reporting, an authorized pit registration system, regulatory filing/permitting upgrades, an underground injection well investigation team, site remediation support, and especially $100 million for orphan well plugging. Members asked about biennium-to-biennium comparisons, salary biennialization, the scale of orphan well risks, federal funding delays, bonding, and whether the state should rely more on industry or general revenue for plugging costs. Commission leadership explained that orphan wells can threaten water and public safety, that plugging costs have risen sharply, and that current funding is insufficient to keep up with emergency wells and the backlog; they also said the agency is moving to cloud-based systems with cybersecurity protections and that the proposed performance measure may need adjustment if funding does not increase. The Railroad Commission testimony was followed by LBB and agency testimony for the Texas Animal Health Commission. LBB described a $42 million recommendation for 2026-27, an increase overall, but with a reduced FTE cap due to turnover and salary reallocation. The recommendation maintained funding for cattle fever tick work, chronic wasting disease, lab testing through an MOU with Texas A&M’s veterinary diagnostic lab, and a new $5 million spay-and-neuter pilot program, while deleting a capital budget rider and adjusting riders tied to entry point inspection stations and clinical trials. Agency leadership then outlined the commission’s mission to protect livestock health and the state’s $22 billion animal industry, and described major disease threats including highly pathogenic avian influenza, cattle fever ticks, New World screwworm, and chronic wasting disease. Their exceptional items focused on recruiting and retaining veterinarians, replacing fleet vehicles, creating an ectoparasite identification lab, adding field staff and IT support, improving records and epidemiology reporting, strengthening central administration, supporting secure food supply planning, expanding chronic wasting disease work, and staffing the new spay-and-neuter program. Members asked about field identification of ticks, the use of disinfectants and PPE, fleet management, the scale of cattle fever tick risk, and chronic wasting disease; the agency explained its current inspection and lab-confirmation process, its reliance on field disinfecting and biosecurity, and the need for more staff and better data systems to keep pace with growing workloads and disease threats.

Transcript Highlights:

• laboratory testing.
• laboratory testing reimbursement.
• The intent of this bill is to create a new process for laboratory claim integrity programs to insert
• and curb wasteful clinical laboratory tests.
• What are soft stopgaps, talking to physicians, make sure anything, everything's clinically reliable,

Transcript Highlights:

• I'll try to keep it quick so everyone can go home, but I am one of 25 boarded clinical laboratory specialists
• I don't understand why clinical laboratories have to have an additional inspection in addition to, as
• The CDPH more than tripled clinical laboratory scientist personnel fees, while facility fees increased
• I urge you to do a thorough inquiry into the more than tripling of my clinical laboratory license.
• I'm here in opposition to this proposal to increase laboratory licensing fees, including raising clinical

Keywords: 987, senate, all

Bills: HB1952, HB1951, HB1929, HB2497, HB2208, HB2572, HB1737, HB1953, HB2551, HB2549

Keywords: HB1952, Hawaii agriculture, University of Hawaii, CTAHR, College of Tropical Agriculture and Human Resilience, Kauai, agricultural research station, extension station, capital improvements, general obligation bonds, GO bonds, appropriation, ADA compliance, Americans with Disabilities Act, certified kitchen, greenhouse, laboratory, field research, cesspool decommissioning, invasive species

Transcript Highlights:

• There's no clinical research.
• That's for the laboratory.
• That's for the laboratory.
• conducts Laboratory laboratory that conducts Laboratory Testing<03:20:33.880><c> for</c><03:20:34.120
• Rabies clinic all the way to a lot of work in our laboratory, but it's generally for disease prevention

Keywords: 928, house, all

Summary: The Finance Division III work session focused on the Department of Health and Human Services’ Division of Public Health Services budget. Department staff said Public Health has a relatively small budget compared with other DHHS divisions, is supported mostly by federal and other non-General funds, and contains nearly 100 accounting units and more than 50 federal grants. They emphasized that the governor’s budget did not include significant cuts, but that federal funding uncertainty and the winding down of pandemic-era resources were major factors affecting the division. The division also explained that some apparent budget growth reflects reorganizations, including moving the Bureau of Emergency Preparedness, Response, and Recovery and some programs from other DHHS divisions into Public Health. The presentation described Public Health’s mission as serving the entire state through food and water safety, disease surveillance, emergency response, maternal and child health, chronic disease prevention, WIC, community health center support, and public health data collection. Members asked about bird flu, and staff explained that human-health response would involve Public Health’s lab, infectious disease, and emergency preparedness units, while animal-health issues are handled with the Department of Agriculture; they also noted ongoing milk testing requested by FDA and USDA. The division said its organizational structure includes bureaus for Family Health and Nutrition, Infectious Disease Control, Public Health Protection, Emergency Preparedness, Prevention and Wellness, Statistics and Informatics, and Public Health Laboratories, with about a 15% vacancy rate. Committee members questioned whether the division’s budget and staffing had really grown since pre-COVID, and staff responded that full-time authorized staffing is about the same as in 2018, with the increase largely due to federal pandemic funding that has since receded and to program transfers between divisions. They said Public Health’s General Fund share is about $24 million out of roughly $1.1 billion in DHHS General Fund spending, or about 2.2% of the department total. Members also asked about the 3,000-position cap and unfunded positions; staff explained that the cap remains in chapter law through June 30, 2025, that 394 positions were unfunded in the governor’s budget, and that the division expects flexibility to move money from personnel lines and fill unfunded positions to manage changing needs. No votes or formal actions were taken in this portion of the work session.

Transcript Highlights:

• </c> University of Minnesota or Mayo Clinic University of Minnesota or Mayo Clinic they<00:42:53.040>
• </c> training for the mobile dental clinic training for the mobile dental clinic the<00:59:06.760><c>
• ><c> a</c><00:59:08.200><c> vital</c> the mobile dental clinic is a vital the mobile dental clinic is
• That's the mobile dental clinic.
• </c><01:04:35.279><c> translation</c> fund clinical translation fund clinical translation 28.3%<01:04

Keywords: 1187, senate, all

Transcript Highlights:

• I'll try to keep it quick so everyone can go home, but I am one of 25 boarded clinical laboratory specialists
• I don't understand why clinical laboratories have to have an additional inspection in addition to, as
• The CDPH more than tripled clinical laboratory scientist personnel fees, while facility fees increased
• I urge you to do a thorough inquiry into the more than tripling of my clinical laboratory license.
• I'm here in opposition to this proposal to increase laboratory licensing fees, including raising clinical

Summary: The committee first heard May Revision child care and human services items. The Department of Child Support Services described two technical adjustments, which the analyst supported. The Department of Social Services then walked through child care proposals, including a reduction in federal and Proposition 64 funding absorbed through a shift from General Child Care to the Alternative Payment program, a 2.01% child care COLA, disaster-related infrastructure grants, a new administrative support cost structure for Alternative Payment agencies, the removal of prospective pay funding after a federal rule change, a reappropriation for existing infrastructure grants, and estimates of unspent child care funds. The Legislative Analyst’s Office recommended asking for more justification for shifting reductions to CAP, supported the COLA reduction but wanted consistency across programs, recommended removing prospective pay funding, opposed the administrative cost shift, and suggested further review of disaster grant alignment. Members pressed the administration on why more slots would be cut for the same savings, why the COLA was reduced, and whether the administrative percentage would grow over time. The administration said the changes were intended to avoid disrupting currently enrolled families, reflect point-in-time relinquishments and unspent funds, and stabilize contractor operations. Public commenters, including providers, advocates, and county representatives, urged full COLA funding, rejection of child care slot reductions, preservation of prospective pay, and continued investment in child care infrastructure and access. The subcommittee then recessed before moving to health items. In Part B, the Department of State Hospitals presented its May Revision proposals, including a central utility plant replacement project at Metropolitan State Hospital, funding for a continuum electronic health record system, reduced county bed billing authority to reflect phase-in of additional LPS beds, limited contract exemption authority for online clinical subscription services, reversion of prior-year unspent operating funds, and a workforce development proposal to use Behavioral Health Services Act funds instead of General Fund for training programs. The department said the EHR would modernize records and improve continuity of care, and that the contract exemption would prevent delays in essential clinical information services. No votes were taken in the excerpt provided.

Transcript Highlights:

• I'm the clinic director for the Center for Health and Prevention Clinics at Community Action Partnership
• We operate brick-and-mortar facilities, satellite sites, and last year we launched a mobile clinic.
• Even though some schools do have vaccination clinics, that is not...
• Even though some schools do have vaccination clinics, they're not adequate to meet the need.
• These two direct CDC grants support infectious disease mitigation and laboratory services.

Summary: The subcommittee held an oversight hearing on federal actions affecting California’s public health and family planning systems, focusing first on the freeze to Title X family planning funds and then on broader CDC/public health grant terminations. Chair and members described the cuts as abrupt, harmful, and likely to create major gaps in disease surveillance, vaccination, contraception, STI testing, and other preventive services, while also criticizing the federal administration’s explanation that the actions were tied to DEI or civil-rights compliance. The chair thanked Attorney General Bonta for legal action and said the hearing was intended to document the real-world impacts and inform state budget responses. Witnesses from Essential Access Health, Planned Parenthood Affiliates of California, a Central Coast clinic, and other providers said California’s Title X network serves more than half a million low-income patients annually and relies on the funds for staffing, outreach, training, mobile and school-based clinics, and confidential care. They warned that the freeze has already forced reserve spending, delayed services, and could lead to layoffs, reduced hours, longer waits, and fewer appointments, especially for sexual and reproductive health care. Public comment included support for a proposed state backfill of Title X losses, with advocates emphasizing impacts on low-income, LGBTQ+, and communities of color. On the public health side, CDPH, county health officials, and local health officers testified that the CDC’s rescission of $11.4 billion in grants would affect California by an estimated $840 million and threaten lab capacity, immunization programs, health disparities work, and data systems such as CalConnect and vaccine registries. Sacramento County and others described how the grants supported outbreak response, sequencing, community vaccination clinics, and equity-focused partnerships, and said terminations had already led to canceled appointments, stopped contracts, and layoffs. Several speakers urged the Legislature to preserve and expand state “future of public health” funding and to backfill federal losses, while public commenters from HIV, immunization, labor, and county organizations echoed concerns about workforce losses and worsening health outcomes.

Transcript Highlights:

• There are public clinical reports... ...many other clinical manifestations.
• I would say that... ...that most forensic laboratories have that capacity to do that.
• So mitragynine was the principal component for forensic laboratories to look into.
• Overdose implies also that it can be prescribed in clinical trials and that.
• That claim is based on zero clinical trials and zero observational studies.

Keywords: 987, senate, all

Transcript Highlights:

• It also has the potential to harm California's doctors, hospitals, clinics, and providers.
• In addition, data about vaccines is delivered through VMS-supported clinics.
• The next proposal relates to our laboratory field sciences fees. This one has a lot of components.
• That's the laboratory field sciences fees.
• Bruce Palmer, California Association of Public Health Laboratories.

Keywords: 988, house, all

Transcript Highlights:

• There are public clinical reports. Any other clinical manifestations.
• I would say that most of the forensic laboratories have that capacity to do that.
• So mitragynine was the principal component for forensic laboratories to look into.
• Overdose implies also that it can be prescribed in clinical trials and that.
• That claim is based on zero clinical trials and zero observational studies.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. Members referenced AB 1088, which would be considered later, and said the hearing was intended to clarify the science, medical perspective, and whether stronger safeguards are needed. The first panel featured a toxicology expert, state and local public health officials, an emergency/addiction physician, a medical examiner, and county health representatives. Witnesses from CDPH and Los Angeles County described rising deaths and enforcement actions, including statewide advisories, retailer letters, and product removals from manufacturers, wholesalers, and retailers. Medical testimony emphasized that 7-OH acts much more like an opioid than traditional kratom leaf, can cause dependence, withdrawal, and respiratory depression, and may require naloxone, buprenorphine, or methadone in overdose or withdrawal cases. Local officials said enforcement is difficult because packaging is inconsistent, testing capacity is limited, and counties lack resources and statewide infrastructure; they generally favored a centralized state framework if regulation is pursued. Committee members asked about testing, age restrictions, scheduling, and whether a distinction between kratom and 7-OH could be enforced. Witnesses said forensic labs can potentially test for 7-OH but validated assays are not routine, emergency departments cannot readily distinguish exposures, and local health departments do not have the lab capacity to verify product labels. Several officials warned that a ban or abrupt scheduling could push products into the black market and discourage research, while others argued that current prohibition and enforcement are the most protective approach because legalization or age-limited regulation could create confusion about legality and safety. The second panel included kratom and 7-OH advocates and industry representatives, who argued that natural kratom leaf and concentrated or synthetic 7-OH are different products and should be regulated differently. They supported age-gating, labeling, testing, and packaging rules for kratom leaf while opposing a ban on the botanical. They said 7-OH is used by many adults for pain relief or harm reduction, and that prohibition would drive consumers to illicit markets and worsen harm. Committee members pressed them on whether 7-OH is more potent than kratom, the availability of testing, and whether any safe dose is known. The hearing ended without a vote or formal action, with the chair noting the issue will continue to be considered in future legislation.

Transcript Highlights:

• There are public clinical reports.
• I would say that most of the forensic laboratories have that capacity to do that.
• So mitragynine was the principal component for forensic laboratories to look into.
• Overdose implies also that it can be prescribed in clinical trials and that.
• That claim is based on zero clinical trials and zero observational studies.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful for consumption, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. The hearing was framed as part of ongoing legislative work, including a future review of AB 1088, and members emphasized the need to weigh potential benefits against risks and consider whether stronger safeguards are needed. Expert testimony from a toxicology professor and several public health and medical officials described kratom as a plant with multiple alkaloids, with 7-OH identified as the more potent opioid-like compound associated with tolerance, dependence, withdrawal, and respiratory depression. CDPH reported 362 kratom-related overdose deaths in California from 2019 to 2023 and 15 deaths involving 7-OH, while Los Angeles County officials described unexplained deaths in young adults that led them to expand toxicology testing and identify 7-OH as a common factor. County and state public health representatives said they have issued advisories, contacted retailers, removed products from shelves, and taken enforcement actions, but they stressed that local enforcement is patchy, under-resourced, and limited by unclear jurisdiction and lack of testing capacity. Medical witnesses said patients are presenting with 7-OH dependence and withdrawal in ways similar to fentanyl-related cases, sometimes requiring buprenorphine, methadone, or repeated naloxone. They argued that unregulated retail sales and misleading marketing make the products especially risky, and that a statewide framework would be more effective than a patchwork of local ordinances. Some officials said the safest current policy is to keep kratom and 7-OH unlawful for consumption, while others said any new regulation would need resources, packaging rules, and clearer authority for enforcement. Industry and consumer advocates urged the committee to distinguish natural kratom leaf from concentrated or synthetic 7-OH products. They argued that kratom leaf has long-standing use, that 7-OH should be targeted rather than the whole plant, and that regulation should focus on age limits, labeling, testing, serving-size caps, and restrictions on adulterated products rather than prohibition. Several speakers warned that bans could push demand to the black market and reduce access for people using the products for pain relief or harm reduction, while critics of the industry said the products are being marketed deceptively and that more comprehensive regulation is needed.

Transcript Highlights:

• Section 29 was of Senate Bill 2016 is the training, education, and clinicals, and health, or the TEACH
• and students at federally qualified health centers, community mental health centers, rural health clinics
• statute under Chapter 408.07, and offer an accredited residency program or fellowship program in clinical
• Coming in behind the MMTCs are the private laboratories who are certified by the department to do the
• I've mentioned the importance of the laboratories and backing up the MMTCs.

Summary: The Senate Health Policy Committee received updates from the Agency for Health Care Administration and the Department of Health on implementation of 2024 health care laws. AHCA reviewed progress on workforce and reimbursement measures in Senate Bill 7016 and related bills, including FRAME and TEACH funding, graduate medical education reporting, behavioral health teaching hospitals, acute hospital care at home, advanced birth centers, non-emergent care access plans, and rural emergency hospitals. Agency officials said several programs are already operational or have begun payments, while others are still in rulemaking, federal approval, or report-preparation stages. Senators asked about timing, funding reversion concerns, and whether appropriated dollars would be spent on schedule, especially for behavioral health teaching hospitals and the new birth center category. The Department of Health then reported on practitioner licensure and public health programs. MQA described implementation of the Interstate Medical Licensure Compact, the Mobile Act licensure pathway, massage therapy enforcement changes, background screening expansion, liposuction safety requirements, pharmacist HIV post-exposure prophylaxis authority, and chiropractic dry needling. Public health staff updated the committee on FRAME and dental loan repayment, the Sinati screening grant program, the cancer research and innovation changes, the health care innovation council and loan program, the pediatric rare disease grant program, telehealth maternity care expansion, newborn screening for congenital CMV, the sickle cell registry and grants, and the swimming lesson voucher program. Members focused questions on how practitioners were being recruited to underserved areas, the pace of licensure approvals, and whether new programs were on track to use appropriated funds. The committee also heard a lengthy update from the Office of Medical Marijuana Use. The director reported more than 900,000 qualified patients, real-time seed-to-sale tracking now integrated across most dispensaries and labs, and ongoing compliance work on product testing, advertising, diversion, and patient safety. Senators questioned the decline in qualified physicians, how THC potency is labeled and verified, and what the agency can do about diversion to non-patients. The director said the office relies on complaints, inspections, lab audits, and coordination with law enforcement, and that patients can be suspended if violations are confirmed.

Transcript Highlights:

• Our laboratories and state-of-the-art facilities need to be utilized and maintained in order to remain
• Our law school clinical programs, there are 13 in all, contribute approximately...
• We typically, in any radiation clinic in those hospitals, you will find Suffolk graduates.
• So last year, in partnership actually with MIT and Harvard, we launched our seed clinic, which is now
• Our laboratories have spun out an amazing 1226 companies.

Keywords: 995, all

Summary: The committee held an informational hearing on the economic impact of Massachusetts higher education institutions, with opening remarks noting the significance of September 11 and the role colleges and universities play in the state’s economy, workforce, and research ecosystem. UMass leaders testified first, describing UMass as a major employer and economic driver that educates large numbers of Massachusetts residents, supports thousands of jobs, and generates billions in annual economic activity. They emphasized the importance of research funding, warned that federal grant cancellations, suspensions, and slowdowns were harming research operations and talent retention, and voiced strong support for Governor Healey’s proposed DRIVE initiative as bridge funding to protect research capacity and jobs. Committee members focused heavily on workforce preparation in emerging fields such as AI, cyber, quantum computing, and engineering. UMass leaders said AI is being embedded across curricula and research, but also warned that financial constraints forced reductions in PhD admissions, especially in computer science and engineering, which could weaken the future workforce pipeline. They also described the practical effects of grant uncertainty, including reduced graduate admissions and concerns about losing researchers to institutions abroad. Members asked for more detailed data on grant timing, funding gaps, and where students and researchers were going. A second panel from private colleges and universities, including AICUM, Suffolk, Smith, and Clark, highlighted the broad economic and civic contributions of private higher education. Testimony cited large annual economic impacts, job creation, tax revenue, community service, legal clinics, dual enrollment, entrepreneurship support, sustainability investments, and access programs. Speakers also discussed enrollment pressures, COVID-related social and mental health challenges, student visa and federal policy concerns, and the need to preserve liberal arts alongside career-focused training. The committee then heard from MIT, where testimony focused on research commercialization, biotech spinouts, and the role of federal, philanthropic, and industry funding in sustaining innovation; members pressed for more data on funding sources and asked what state policy could do to keep talent and businesses in Massachusetts. The hearing continued with additional public higher education testimony, including Bridgewater State, Bristol Community College, and Northeastern, which emphasized workforce-aligned programs, social mobility, apprenticeships, co-op education, and the need for better coordination between higher education, employers, and state workforce systems.

Transcript Highlights:

• They can run laboratories, they can order laboratories, and things of that nature.
• Tab 14 is Senate Bill 878 on clinical laboratory personnel by Senator Yarbrough, and Senator Yarbrough
• The laboratory industry... Thank you, Madam Chair. Good afternoon. Senate Bill 878.
• , and medical laboratory scientists.
• Laboratory Improvement Amendments, or CLIA, standards. ...complex testing under federal Clinical Laboratory

Summary: The committee first heard Senate Bill 1414 by Sen. Polsky on congenital cytomegalovirus (CMV) education. The bill would require the Department of Health, working with medical experts, to create and distribute CMV educational materials to expectant and new parents or caregivers through hospitals, birth centers, and OB/GYN practices. An amendment removed a section that would have required instruction for medical professionals, and the amended bill was reported favorably as a committee substitute. The committee then took up a block of confirmations. Appointees on tabs 2 through 7 were recommended favorably in one vote, and Chavon Harris was separately confirmed as Secretary of the Agency for Health Care Administration after extensive questioning. Senators praised her leadership and experience, while others raised concerns about Medicaid redeterminations, the state’s CORE modernization project, Hope Florida, and a DCF anti-marijuana ad campaign; Harris said she would follow up on some issues and defended the agency’s work on transparency, managed care oversight, and access to care. Her confirmation was recommended favorably, with Sen. Berman noting opposition. Several health-related bills were then heard and advanced. SB 186 by Sen. Garcia expanded epilepsy training requirements for school personnel, including charter school bus drivers, and was reported favorably. SB 902 by Sen. Garcia, after amendments narrowing dental workforce provisions and allowing certain seizure rescue medication delegation to family home health aides, was reported favorably; testimony focused on medical marijuana regulation, practitioner accountability, and concerns about park and child-care proximity restrictions. SB 196 by Sen. Sharif created a uterine fibroid research database with privacy protections and was reported favorably after emotional testimony from a patient and supporters. SB 688 by Sen. Rodriguez would reestablish licensure of naturopathic doctors; it drew both support and skepticism about diagnosis and treatment boundaries, but was reported favorably. SB 1574, Maddie’s Law, would add biliary atresia screening to newborn screening and was strongly supported by parents describing a delayed diagnosis; it was reported favorably. SB 878 on clinical laboratory personnel, SB 1092 on podiatric medicine and certain cellular/tissue-based products, and SB 1032 on medical marijuana registry timelines and veteran fee waivers were also reported favorably, while SB 1032 drew debate over longer renewal/supply periods. The committee then began SB 1760 on Medicaid oversight and program transparency, with the sponsor describing the bill’s creation of a joint legislative oversight committee and a legislative actuary.